Key Highlights
- Adaptive Biotechnologies shares reached a 52-week high following a positive reaction to second quarter 2026 Earnings reported on August 5, 2026.
- Revenue rose 21.5 percent year-over-year to USD 71.6 million, though the company posted a net loss of USD 39.8 million.
- clonoSEQ test volumes increased 42 percent year-to-date to 68,706 tests, driving MRD Revenue up 42 percent.
- Total revenue growth reached 28 percent year-to-date, aided by expanded Medicare coverage.
A Genomic Platform for Immune-Driven Diagnostics
Adaptive Biotechnologies develops and commercializes immune-driven diagnostics and drug discovery technologies, with its clonoSEQ test serving as a leading minimal residual disease assay used in blood cancer monitoring. The company's platform leverages its proprietary immune sequencing technology to detect minimal residual disease with high sensitivity, supporting oncologists in tracking treatment response over time.
MRD Growth Offset Declines in Immune Medicine
Adaptive Biotechnologies reported second quarter 2026 results with revenue of USD 71.6 million, up from USD 58.9 million a year earlier, a 21.5 percent increase. The company recorded a net loss of USD 39.8 million, wider than the USD 25.6 million loss in the prior-year quarter. MRD revenue rose sharply, with clonoSEQ tests increasing 42 percent year-to-date to 68,706, helping drive total revenue growth of 28 percent year-to-date, even as Immune Medicine revenue declined 48 percent year-to-date following the termination of the Genentech collaboration.
A Positive Reaction Despite a Wider Loss
The stock's move to a 52-week high reflects a positive market reaction to the results, as investors appear to have focused on the scale of clonoSEQ's growth and expanded Medicare coverage rather than the widening net loss, which was driven substantially by the wind-down of the lower-margin Immune Medicine business.
A Business in Transition Toward Its Highest-Margin Segment
Continued growth in clonoSEQ volumes and improved MolDX episode pricing could support further momentum if the shift toward MRD testing continues to outweigh the declining Immune Medicine business. The company is pursuing separation of its Immune Medicine and MRD businesses, a structural change that could sharpen investor focus on the stronger-performing segment, though execution risk remains around how cleanly that separation can be achieved.
Conclusion
Adaptive Biotechnologies' move to a 52-week high reflects a positive market response to accelerating clonoSEQ growth, even as the company's overall net loss widened due to the wind-down of its Immune Medicine business. Expanded Medicare coverage and pricing gains have reinforced confidence in the durability of the MRD franchise. Continued momentum will likely depend on execution of the planned business separation and sustained clonoSEQ Volume growth.






Please wait processing your request...